Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Brain : a journal of neurology

• Publication date

  2008-10-24

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/brain/awn235PMID 18952677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson’s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram

  2008cited by this paper
• Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism

  2008cited by this paper
• Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

  2007cited by this paper
• Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial

  2007cited by this paper
• Serotonin Neuron Transplants Exacerbate l-DOPA- Induced Dyskinesias in a Rat Model of Parkinson's Disease

  2007cited by this paper
• The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

  2007cited by this paper
• RGS9–2 Negatively Modulates l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease

  2007cited by this paper
• Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in l-DOPA-Induced Dyskinesia in the Rat

  2006cited by this paper
• Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine.

  2006cited by this paper
• A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia

  2006cited by this paper
• Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia

  2006cited by this paper
• 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease.

  2006cited by this paper
• In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates, the Selective 5-Hydroxytryptamine 1a Agonist (R)-(+)-8-OHDPAT Inhibits Levodopa-Induced Dyskinesia but Only with\ Increased Motor Disability

  2006cited by this paper
• Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia

  2005cited by this paper
• Effects of sarizotan on the corticostriatal glutamate pathways

  2005cited by this paper
• Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.

  2005cited by this paper
• Effects of Acute and Long-Term Administration of Escitalopram and Citalopram on Serotonin Neurotransmission: an In Vivo Electrophysiological Study in Rat Brain

  2005cited by this paper
• Levodopa‐induced dyskinesia in MPTP‐treated macaques is not dependent on the extent and pattern of nigrostrial lesioning

  2005cited by this paper
• 8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease

  2005cited by this paper
• A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.

  2005cited by this paper
• Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia

  2005cited by this paper
• Real‐time decoding of dopamine concentration changes in the caudate–putamen during tonic and phasic firing

  2004cited by this paper
• Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.

  2004cited by this paper
• The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism

  2004cited by this paper
• Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.

  2004cited by this paper
• Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.

  2004cited by this paper
• DAncing past the DAT at a DA synapse.

  2004cited by this paper
• Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.

  2004cited by this paper
• Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study)

  2004cited by this paper
• 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates

  2003cited by this paper
• Real‐time decoding of dopamine concentration changes in the caudate–putamen during tonic and phasic firing

  2003cited by this paper
• Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

  2003cited by this paper
• Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

  2002cited by this paper
• Hippocampal Synaptic Plasticity Involves Competition between Ca2+/Calmodulin-Dependent Protein Kinase II and Postsynaptic Density 95 for Binding to the NR2A Subunit of the NMDA Receptor

  2001cited by this paper
• Activation of 5‐HT1A but not 5‐HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered l‐DOPA in the striatum with nigrostriatal denervation

  2001cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane

  2001cited by this paper
• Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies

  2001cited by this paper
• Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

  2001cited by this paper
• Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

  2001cited by this paper
• Growth and Functional Efficacy of Intrastriatal Nigral Transplants Depend on the Extent of Nigrostriatal Degeneration

  2001cited by this paper
• Levodopa motor complications in Parkinson's disease.

  2000cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors.

  2000cited by this paper
• Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.

  2000cited by this paper
• Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey.

  2000cited by this paper
• Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats.

  1999cited by this paper
• Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.

  1999cited by this paper
• Diabetic Glomerulopathy in Young IDDM Patients

  1998cited by this paper
• L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

  1998cited by this paper
• Differential expression of two vesicular monoamine transporters

  1995cited by this paper
• The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex.

  1994cited by this paper
• Toxin-Induced Models of Neurological Disorders

  1994cited by this paper
• Behavioral Effects of MPTP Administration in the Vervet Monkey

  1994cited by this paper
• Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase.

  1994cited by this paper
• A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia

  1992cited by this paper
• The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice.

  1988cited by this paper
• Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome.

  1986cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983influential reference
• The site of dopamine formation in rat striatum after L-dopa administration.

  1981cited by this paper
• Nonaminergic striatal neurons convert exogenous l‐dopa to dopamine in parkinsonism

  1980cited by this paper
• Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity.

  1979cited by this paper
• Effects of L-Dopa on Efflux of Cerebral Monoamines from Synaptosomes

  1971cited by this paper
• L-Dopa-Induced Release of Cerebral Monoamines

  1970cited by this paper
• Brain

  1878cited by this paper

• Involvement of Neuroinflammation and Oxidative Stress in L-DOPA-Induced Dyskinesia in Parkinson’s Disease: Role of Renin–Angiotensin System and ROCK Pathway

  2025cites this paper
• Dopamine and serotonin cotransmission filters striatonigral synaptic activity via 5-HT1B receptor activation

  2025cites this paper
• Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson’s Disease

  2025cites this paper
• Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons

  2024cites this paper
• The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson’s disease

  2024cites this paper
• 5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice.

  2024cites this paper
• Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms

  2024cites this paper
• Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

  2024cites this paper
• Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study

  2024cites this paper
• First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells

  2023cites this paper
• Multimodal imaging study of the 5-HT1A receptor biased agonist, NLX-112, in a model of L-DOPA-induced dyskinesia

  2023cites this paper
• Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia

  2023cites this paper
• How and why the adenosine A2A receptor became a target for Parkinson's disease therapy.

  2023cites this paper
• Role of P11 through serotonergic and glutamatergic pathways in LID

  2023cites this paper
• Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia.

  2023cites this paper
• Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia

  2023cites this paper
• Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

  2022cites this paper
• The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.

  2022cites this paper
• Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment

  2022cites this paper
• An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson’s Disease

  2022cites this paper
• Disminución de las discinesias en un modelo de Parkinson en ratas Wistar, mediada por el fitofármaco Mucuna pruriens

  2021cites this paper
• Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update.

  2021cites this paper
• Parkinson's disease in Women: Mechanisms underlying sex differences.

  2021cites this paper
• Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence.

  2021cites this paper
• Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders.

  2021cites this paper
• Molecular Sciences L-DOPA in Parkinson’s Disease: Looking at the ”False” Neurotransmitters and Their Meaning

  2021cites this paper
• Serotonergic control of the glutamatergic neurons of the subthalamic nucleus.

  2021cites this paper
• Synergistic Effect of Serotonin 1A and Serotonin 1B/D Receptor Agonists in the Treatment of L-DOPA-Induced Dyskinesia in 6-Hydroxydopamine-Lesioned Rats

  2021cites this paper
• Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems.

  2020cites this paper
• Anxiety: An ignored aspect of Parkinson's disease lacking attention.

  2020cites this paper
• Parkinson’s Disease

  2020cites this paper
• An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

  2020influential citation
• Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: A systematic review

  2020influential citation
• Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.

  2020cites this paper
• Rho kinase inhibitor fasudil reduces l‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease

  2020cites this paper
• Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA

  2020cites this paper
• The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets

  2020cites this paper
• The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease

  2020cites this paper
• Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

  2020cites this paper
• Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update

  2020cites this paper
• Clinical implication of high-density EEG sleep recordings in Parkinson's disease.

  2020cites this paper
• Nicotinic acetylcholine receptors in experimental models of Parkinson’s disease and levodopa-induced dyskinesia : focus on α5 subunit-containing receptors

  2019cites this paper
• Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects

  2019cites this paper
• Comprehensive mapping of neurotransmitter networks by MALDI–MS imaging

  2019cites this paper
• Serotonin Receptors as the Therapeutic Target for Central Nervous System Disorders

  2019cites this paper
• Eltoprazine prevents levodopa‐induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate

  2019cites this paper
• Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update

  2019cites this paper
• Dorsal GPi/GPe Stimulation Induced Dyskinesia in a Patient with Parkinson’s Disease

  2019cites this paper
• L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning

  2019cites this paper
• Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia

  2019cites this paper
• The role of dopamine and serotonin in cervical dystonia

  2018cites this paper
• Molecular Imaging of the Serotonergic System in Parkinson's Disease.

  2018cites this paper
• Diverse serotonin actions of vilazodone reduce l‐3,4‐dihidroxyphenylalanine–induced dyskinesia in hemi‐parkinsonian rats

  2018cites this paper
• Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?

  2018cites this paper
• Interactions of the tricyclic antidepressant drug amitriptyline with L‐DOPA in the striatum and substantia nigra of unilaterally 6‐OHDA‐lesioned rats. Relevance to motor dysfunction in Parkinson's disease

  2018cites this paper
• Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey

  2018cites this paper
• 5-HT1A receptor ligands and their therapeutic applications: review of new patents

  2018cites this paper
• Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers

  2018cites this paper
• Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease

  2018cites this paper
• Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias

  2018cites this paper
• The role of serotonergic and dopaminergic mechanisms and their interaction in Levodopa-induced dyskinesias

  2018influential citation
• The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective

  2018cites this paper
• Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia

  2018cites this paper
• Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model

  2018cites this paper
• Cholinergic control of striatal neurons to modulate L‐dopa‐induced dyskinesias

  2018cites this paper
• Pre- and postsynaptic dysregulation of dopamine signalling in Parkinson's disease

  2018cites this paper
• La Enfermedad de Parkinson: Etiología, Tratamientos y Factores Preventivos

  2017cites this paper
• BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.

  2017cites this paper
• 5-HT1a activation in PO/AH area induces therapeutic hypothermia in a rat model of intracerebral hemorrhage

  2017cites this paper
• Levodopa pharmacokinetics -from stomach to brain : A study on patients with Parkinson’s disease

  2017cites this paper
• Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.

  2017cites this paper
• l‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?

  2017cites this paper
• Control of Motor Function by Adenosine A2A Receptors in Parkinson's and Huntington's Disease

  2017cites this paper
• Levodopa Pharmacokinetics in Brain after Both Oral and Intravenous Levodopa in One Patient with Advanced Parkinson’s Disease

  2017influential citation
• Molecular Mechanisms of l-DOPA-Induced Dyskinesia

  2017cites this paper
• Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

  2017cites this paper
• Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms

  2017cites this paper
• Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications

  2017cites this paper
• A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L‐DOPA‐induced dyskinesia in Parkinson's disease

  2017cites this paper
• Synthesis, biological evaluation and molecular modeling of 1-oxa-4-thiaspiro- and 1,4-dithiaspiro[4.5]decane derivatives as potent and selective 5-HT1A receptor agonists.

  2017cites this paper
• The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies

  2017cites this paper
• Non-dopamine receptor ligands for the treatment of Parkinson’s disease. Insight into the related chemical/property space

  2016cites this paper
• A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine‐rich repeat kinase 2 mutation carrier

  2016cites this paper
• Anatomical and functional characterization of serotonergic neurocircuitry

  2016cites this paper
• Serotonin transporter in Parkinson's disease: A meta‐analysis of positron emission tomography studies

  2016cites this paper
• Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.

  2016cites this paper
• Polimorfizam gena za serotoninski receptor 5-HT1A i motoričke popratne pojave antipsihotika haloperidola

  2016cites this paper
• Serotonin-to-dopamine transporter ratios in Parkinson disease

  2016cites this paper
• Permeability of blood–brain barrier in macaque model of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced Parkinson disease

  2016cites this paper
• Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson's Disease.

  2016cites this paper
• Antiparkinsonian Treatment for Depression in Parkinson's Disease: Are Selective Serotonin Reuptake Inhibitors Recommended?

  2016cites this paper
• Dopamine Receptor Agonists: New Formulations and New Potentials in the Treatment of Parkinson’s Disease

  2016cites this paper
• Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease

  2016cites this paper
• Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.

  2016cites this paper
• Агонисты дофаминовых рецепторов: новые формы и новые возможности в лечении болезни Паркинсона

  2015cites this paper
• NEUROPHYSIOLOGICAL TRACES OF L-DOPA INDUCED DYSKINESIA IN THE BED NUCLEUS OF THE STRIA TERMINALIS OF 6-OHDA LESIONED RATS

  2015cites this paper
• Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?

  2015influential citation
• Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.

  2015cites this paper
• Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.

  2015cites this paper
• New insight into the therapeutic role of the serotonergic system in Parkinson's disease.

  2015cites this paper